Table 1.
Clinicopathologic Characteristics of Rhabdomyosarcoma With and Without Anaplasia. (IRSG/COG studies – 1995–1998)
| Anaplasia | |||
|---|---|---|---|
| None (n=474) | Focal (n=40) | Diffuse (n=32) | |
| AGE (YEARS) | |||
| <1 | 18 | 3 (14%) | - |
| 1–9 | 296 | 19(6%) | 26 (8%) |
| 10+ | 157 | 18(10%) | 6 (3%) |
| Unknown | 3 | - | - |
| RACE | |||
| White | 333 | 24 (6%) | 23 (6%) |
| Non-white | 137 | 16 (10%) | 9 (6%) |
| SEX | |||
| Male | 300 | 26 (8%) | 19 (6%) |
| Female | 174 | 14 (7%) | 13 (7%) |
| CLINICAL GROUP | |||
| I | 86 | 10 (10%) | 10 (10%) |
| II | 50 | 7 (12%) | 3 (5%) |
| III | 249 | 16 (6%) | 8 (3%) |
| IV | 84 | 7 (7%) | 11 (11%) |
| Unknown | 4 | - | 1 |
| STAGE | |||
| 1 | 155 | 20 (11%) | 11 (6%) |
| 2 | 76 | 3 (2%) | 5 (6%) |
| 3 | 158 | 10 (6%) | 5 (3%) |
| 4 | 84 | 7 (7%) | 11 (11%) |
| Unknown | 1 | - | - |
| PRIMARY SITE | |||
| All Favorable Sites | 163 | 24 (12%) | 13 (7%) |
| Orbit | 49 | 4 (7%) | 3 (5%) |
| Head and neck/non-PM | 32 | 4 (11%) | 2 (5%) |
| GU, non-bladder/prostate | 82 | 16 (15%) | 8 (8%) |
| All Unfavorable Sites | 311 | 16 (5%) | 19 (5%) |
| Parameningeal | 97 | 2 (2%) | 2 (2%) |
| Parameningeal extension | 11 | 1 (8%) | 0 |
| Bladder/prostate | 49 | 2 (4%) | 2 (4%) |
| Extremity | 63 | 4 (5%) | 10 (13%) |
| Other | 91 | 7 (7%) | 5 (5%) |
| Tumor Invasiveness | |||
| T1 | 219 | 21 (8%) | 17 (7%) |
| T2 | 247 | 19 (7%) | 15 (5%) |
| Unknown | 8 | - | - |
| Nodal involvement | |||
| N0 | 351 | 28 (7%) | 25 (6%) |
| N1 | 93 | 7 (7%) | 6 (6%) |
| Unknown | 30 | 5 | 1 |
| Tumor size | |||
| ≤ 5cm | 216 | 19 (7%) | 19 (7%) |
| > 5 cm | 249 | 21 (7%) | 13 (5%) |
| Unknown | 9 | - | - |